|[February 21, 2013]
Fibrocell Adds New Member to its Board
EXTON, Pa. --(Business Wire)--
Fibrocell Science, Inc. (OTC: FCSC) announced today that Christine
St.Clare, a former KPMG LLP partner, joined the Company's Board of
Directors effective February 21, 2013. She will serve as Chair of the
Audit Committee. The Fibrocell Board now consists of seven members.
Ms. St.Clare recently completed a 35-year career with KPMG where she
served a four-year term on the firm's Board of Directors and chaired the
board's Audit and Finance Committee. As an Audit Partner, she served as
the Engagement Partner for some of KPMG's largest clients. She then
assumed the position as an Advisory Partner for the firm's Advisory
Practice focusing on the Internal Audit, Risk and Compliance Practice.
Concurrently, she was the Partner-in-Charge of the Southeast Consumer
"We are delighted to welcome Christine to our Board of Directors," said
David Pernock, Chief Executive Officer and Board Chair of Fibrocell
Science. "She is highly regarded and brings a rich level of expertise
that is especially important to our future growth."
Ms. St.Clare has also played a leadership role in developing programs
and initiatives to encourage the retention and advancement of women into
meaningful positions. She was a founding member of KPMG's Women's
Advisory Board reporting to the firm's U.S. Chairman. She urrently
serves on the advisory boards of Houlihan Lokey, a midsize global,
advisory-focused investment bank, Women Corporate Directors, and Emory
University's Goizueta Business School.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (FCSC) is an autologous cellular therapeutic
company focused on the development of innovative products for aesthetic,
medical and scientific applications. Fibrocell Science is committed to
advancing the scientific, medical and commercial potential of autologous
skin and tissue, as well as its innovative cellular processing
technology and manufacturing excellence. For additional information,
please visit www.fibrocellscience.com.
All statements in this press release that are not based on historical
fact are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 and the provisions of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. While management has based
any forward-looking statements contained herein on its current
expectations, the information on which such expectations were based may
change. These forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of the
Company's control, that could cause actual results to materially differ
from such statements. Such risks, uncertainties, and other factors
include, but are not necessarily limited to, those set forth under Item
1A "Risk Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2011, as updated in "Item 1A. Risk Factors" in
the Company's Quarterly Reports on Form 10-Q filed since the annual
report. The Company operates in a highly competitive and rapidly
changing environment, thus new or unforeseen risks may arise.
Accordingly, investors should not place any reliance on forward-looking
statements as a prediction of actual results. The Company disclaims any
intention to, and undertakes no obligation to, update or revise any
forward-looking statements. Readers are also urged to carefully review
and consider the other various disclosures in the Company's public
filings with the SEC (News - Alert).
[ Back To TMCnet.com's Homepage ]